CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

RBC Cuts Price Target on Neumora Therapeutics to $5 From $7, Keeps Outperform, Speculative Risk

Negative
AI Analysis

Summary

RBC Capital Markets reduced its price target on Neumora Therapeutics from $7 to $5 while maintaining an Outperform rating, citing speculative risk.

Importance:3/10
Sentiment:
-0.30
price_target_reductionanalyst_ratingvaluation
Related Companies

Read the original article

Published by yahoo_finance on July 13, 2026 10:30 AM

Read Original